29 Quotes by Paul Donovan

We believe we can close by the end of March.

We factored in the possibility of something like this happening. This news is manageable and does not alter our fundamental belief in Guidant's long-term potential, which is significant and very much intact.

We've reviewed the intellectual property issues and are comfortable proceeding with the transaction. We don't expect this issue to impact the transaction.

If successful, we would combine the resources of two of the leading innovators in cardiovascular medicine and would expand our footprint into cardiac rhythm management. The Guidant acquisition is a natural outgrowth of our strategy to further diversify our business and accelerate growth.

We're pleased to close this chapter, and put this matter behind us. We can now direct our full attention to developing our life-saving products and technologies.

I think there is a reasonable chance we will see another interest rate reduction before the cycle is over, but I don't think it is going to happen quite yet.

Rear-projection technologies will undoubtedly dominate from 50 in. onward. The incremental cost of making them bigger is much less and profit margins remain higher.

We continue to move forward with our due diligence with the goal of reaching a definitive agreement with Guidant.

We continue to move forward on our due diligence with the goal of reaching a definitive agreement with Guidant. I don't think we're going to have anything more to say right now.